Clobetasol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Clobetasol: From Inflammatory Skin Disease to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Clobetasol is a super-potent topical corticosteroid, marketed in South Africa as a cream and an ointment. The SAHPRA data supplied do not state its approved indication. The TxGNN model predicts it may be effective for primary cutaneous T-cell lymphoma (score 99.51%), but no clinical trials or publications were retrieved under this exact label. Related evidence sits under the neighbouring label “lymphosarcoma” and consists of 20 publications (10 supplied for review), mostly early-stage mycosis fungoides studies and case reports.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration data supplied |
| Predicted New Indication | Primary cutaneous T-cell lymphoma |
| TxGNN Prediction Score | 99.51% (model rank 2,859) |
| Evidence Level | L5 for this label (provisional L3 under the related “lymphosarcoma” label) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this drug. Clobetasol is a topical glucocorticoid. As a general assumption not backed by the supplied data, a potent glucocorticoid could act on skin-homing malignant T cells through glucocorticoid-receptor anti-inflammatory and pro-apoptotic effects.
The link between the drug’s usual use and the predicted indication is skin-localised disease. Early-stage cutaneous T-cell lymphoma (mycosis fungoides) is a lymphoma confined to the skin. Its patches and plaques can be treated with topical agents applied directly to the lesions.
The papers retrieved for mycosis fungoides were filed under the label “lymphosarcoma”, not “primary cutaneous T-cell lymphoma”. These two labels should be reconciled before any decision is made. The plausible mechanism is local, so it would not extend to nodal or systemic lymphoma.
Clinical Trial Evidence
Currently no related clinical trials registered for primary cutaneous T-cell lymphoma.
For the related “lymphosarcoma” label, one Phase 3 trial was retrieved (NCT01313221, etanercept in plaque psoriasis). It has no evident link to clobetasol for lymphoma, so it is not counted as evidence.
Literature Evidence
No publications were retrieved under the label “primary cutaneous T-cell lymphoma”. The table below shows the most relevant publications retrieved under “lymphosarcoma”. Study types are inferred from titles and abstracts and were not verified. Only 10 of 20 retrieved papers were supplied.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39741016 | 2025 | Comparative study | Anais Brasileiros de Dermatologia | Clobetasol propionate vs bexarotene in early-stage mycosis fungoides |
| 32603400 | 2020 | Cohort (observational) | Cutis | Skin adverse effects of clobetasol 0.05% cream in early-stage mycosis fungoides |
| 14686970 | 2003 | Clinical experience review | Dermatologic Therapy | About 200 patch-stage patients treated with high-potency topical steroids; response over 90%, minor side effects; clobetasol is first-line for early-stage disease at UCSF |
| 12581145 | 2003 | Not classified | Int J Dermatol | UCSF approach to treating mycosis fungoides and Sézary syndrome |
| 9722724 | 1998 | Not classified | Arch Dermatol | Topical corticosteroids for mycosis fungoides, experience in 79 patients |
| 25027222 | 2014 | Case report | Ned Tijdschr Geneeskd | Child with hypopigmented mycosis fungoides successfully treated with clobetasol 0.05% ointment 4 days a week |
| 16704661 | 2006 | Case report | Br J Dermatol | Topical mechlorethamine plus clobetasol in multifocal cutaneous marginal zone B-cell lymphoma |
| 30677799 | 2018 | Review / case report | Dermatol Online J | Lymphomatoid papulosis, a low-grade CTCL variant, can be monitored off therapy per recent guidelines |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| F/13.4.1/176 | Dermovate | Cream | Not stated in the data supplied |
| 28/13.4.1/0611 | Xenovate | Ointment | Not stated in the data supplied |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
The retrieved literature raises two points that need review:
- Local skin effects: A 2020 observational study in early-stage mycosis fungoides examined skin adverse effects of prolonged clobetasol 0.05% cream (PMID 32603400).
- Systemic effects: A case report describes topical clobetasol as an overlooked cause of Cushing syndrome (PMID 33902425). Prolonged use over large areas of skin, as chronic lymphoma treatment would involve, needs careful monitoring.
Conclusion and Next Steps
Decision: Hold
Rationale: The model score is very high, but no trials or literature were retrieved under the label “primary cutaneous T-cell lymphoma”. The supporting evidence (provisional L3) is observational and sits under a different label. No Phase 3 RCT of clobetasol for lymphoma was found. The plausible mechanism applies only to early-stage skin disease.
To proceed, the following is needed:
- Reconcile the labels “primary cutaneous T-cell lymphoma” and “lymphosarcoma”, and narrow the indication to early-stage mycosis fungoides.
- Verify study designs and grade the full set of 20 papers, since only 10 were supplied.
- Obtain the SAHPRA package insert for both registrations, covering approved indications, warnings and contraindications.
- Obtain mechanism of action data from DrugBank.
- Define a monitoring plan for prolonged use, covering local skin atrophy and systemic corticosteroid effects.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.